Cargando…

4‐phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR‐α

BACKGROUND AND AIMS: 4‐phenylbutyric acid (4‐PBA) is a low molecular weight fatty acid that is used in clinical practice to treat inherited urea cycle disorders. In previous reports, it acted as a chemical chaperone inhibiting endoplasmic reticulum (ER) stress and unfolded protein response signaling...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shu‐Zhen, Ling, Yan, Yu, Le‐Xing, Song, Yu‐Ting, Chen, Xiao‐Fei, Cao, Qi‐Qi, Yu, Han, Chen, Can, Tang, Jiao‐Jiao, Fan, Zhe‐Cai, Miao, Yu‐Shan, Dong, Ya‐Ping, Tao, Jun‐Yan, Monga, Satdarshan P.S., Wen, Wen, Wang, Hong‐Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087947/
https://www.ncbi.nlm.nih.gov/pubmed/33931972
http://dx.doi.org/10.1002/ctm2.379
_version_ 1783686758974619648
author Chen, Shu‐Zhen
Ling, Yan
Yu, Le‐Xing
Song, Yu‐Ting
Chen, Xiao‐Fei
Cao, Qi‐Qi
Yu, Han
Chen, Can
Tang, Jiao‐Jiao
Fan, Zhe‐Cai
Miao, Yu‐Shan
Dong, Ya‐Ping
Tao, Jun‐Yan
Monga, Satdarshan P.S.
Wen, Wen
Wang, Hong‐Yang
author_facet Chen, Shu‐Zhen
Ling, Yan
Yu, Le‐Xing
Song, Yu‐Ting
Chen, Xiao‐Fei
Cao, Qi‐Qi
Yu, Han
Chen, Can
Tang, Jiao‐Jiao
Fan, Zhe‐Cai
Miao, Yu‐Shan
Dong, Ya‐Ping
Tao, Jun‐Yan
Monga, Satdarshan P.S.
Wen, Wen
Wang, Hong‐Yang
author_sort Chen, Shu‐Zhen
collection PubMed
description BACKGROUND AND AIMS: 4‐phenylbutyric acid (4‐PBA) is a low molecular weight fatty acid that is used in clinical practice to treat inherited urea cycle disorders. In previous reports, it acted as a chemical chaperone inhibiting endoplasmic reticulum (ER) stress and unfolded protein response signaling. A few studies have suggested its function against hepatic fibrosis in mice models. However, its role in hepatocarcinogenesis remained unknown. METHODS: 4‐PBA was administered alone or in combination with diethylnitrosamine to investigate its long‐term effect on liver tumorigenesis. The role of 4‐PBA in oncogene‐induced hepatocellular carcinoma (HCC) mice model using sleeping beauty system co‐expressed with hMet and β‐catenin point mutation (S45Y) was also observed. RNA‐seq and PCR array were used to screen the pathways and genes involved. In vitro and in vivo studies were conducted to explore the effect of 4‐PBA on liver and validate the underlying mechanism. RESULTS: 4‐PBA alone didn't cause liver tumor in long term. However, it promoted liver tumorigenesis in HCC mice models via initiation of liver cancer stem cells (LCSCs) through Wnt5b‐Fzd5 mediating β‐catenin signaling. Peroxisome proliferator‐activated receptors (PPAR)‐α induced by 4‐PBA was responsible for the activation of β‐catenin signaling. Thus, intervention of PPAR‐α reversed 4‐PBA‐induced initiation of LCSCs and HCC development in vivo. Further study revealed that 4‐PBA could not only upregulate the expression of PPAR‐α transcriptionally but also enhance its stabilization via protecting it from proteolysis. Moreover, high PPAR‐α expression predicted poor prognosis in HCC patients. CONCLUSIONS: 4‐PBA could upregulate PPAR‐α to initiate LCSCs by activating β‐catenin signaling pathway, promoting HCC at early stage. Therefore, more discretion should be taken to monitor the potential tumor‐promoting effect of 4‐PBA under HCC‐inducing environment.
format Online
Article
Text
id pubmed-8087947
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80879472021-05-07 4‐phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR‐α Chen, Shu‐Zhen Ling, Yan Yu, Le‐Xing Song, Yu‐Ting Chen, Xiao‐Fei Cao, Qi‐Qi Yu, Han Chen, Can Tang, Jiao‐Jiao Fan, Zhe‐Cai Miao, Yu‐Shan Dong, Ya‐Ping Tao, Jun‐Yan Monga, Satdarshan P.S. Wen, Wen Wang, Hong‐Yang Clin Transl Med Research Articles BACKGROUND AND AIMS: 4‐phenylbutyric acid (4‐PBA) is a low molecular weight fatty acid that is used in clinical practice to treat inherited urea cycle disorders. In previous reports, it acted as a chemical chaperone inhibiting endoplasmic reticulum (ER) stress and unfolded protein response signaling. A few studies have suggested its function against hepatic fibrosis in mice models. However, its role in hepatocarcinogenesis remained unknown. METHODS: 4‐PBA was administered alone or in combination with diethylnitrosamine to investigate its long‐term effect on liver tumorigenesis. The role of 4‐PBA in oncogene‐induced hepatocellular carcinoma (HCC) mice model using sleeping beauty system co‐expressed with hMet and β‐catenin point mutation (S45Y) was also observed. RNA‐seq and PCR array were used to screen the pathways and genes involved. In vitro and in vivo studies were conducted to explore the effect of 4‐PBA on liver and validate the underlying mechanism. RESULTS: 4‐PBA alone didn't cause liver tumor in long term. However, it promoted liver tumorigenesis in HCC mice models via initiation of liver cancer stem cells (LCSCs) through Wnt5b‐Fzd5 mediating β‐catenin signaling. Peroxisome proliferator‐activated receptors (PPAR)‐α induced by 4‐PBA was responsible for the activation of β‐catenin signaling. Thus, intervention of PPAR‐α reversed 4‐PBA‐induced initiation of LCSCs and HCC development in vivo. Further study revealed that 4‐PBA could not only upregulate the expression of PPAR‐α transcriptionally but also enhance its stabilization via protecting it from proteolysis. Moreover, high PPAR‐α expression predicted poor prognosis in HCC patients. CONCLUSIONS: 4‐PBA could upregulate PPAR‐α to initiate LCSCs by activating β‐catenin signaling pathway, promoting HCC at early stage. Therefore, more discretion should be taken to monitor the potential tumor‐promoting effect of 4‐PBA under HCC‐inducing environment. John Wiley and Sons Inc. 2021-05-01 /pmc/articles/PMC8087947/ /pubmed/33931972 http://dx.doi.org/10.1002/ctm2.379 Text en © 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Chen, Shu‐Zhen
Ling, Yan
Yu, Le‐Xing
Song, Yu‐Ting
Chen, Xiao‐Fei
Cao, Qi‐Qi
Yu, Han
Chen, Can
Tang, Jiao‐Jiao
Fan, Zhe‐Cai
Miao, Yu‐Shan
Dong, Ya‐Ping
Tao, Jun‐Yan
Monga, Satdarshan P.S.
Wen, Wen
Wang, Hong‐Yang
4‐phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR‐α
title 4‐phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR‐α
title_full 4‐phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR‐α
title_fullStr 4‐phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR‐α
title_full_unstemmed 4‐phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR‐α
title_short 4‐phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR‐α
title_sort 4‐phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of ppar‐α
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087947/
https://www.ncbi.nlm.nih.gov/pubmed/33931972
http://dx.doi.org/10.1002/ctm2.379
work_keys_str_mv AT chenshuzhen 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT lingyan 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT yulexing 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT songyuting 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT chenxiaofei 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT caoqiqi 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT yuhan 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT chencan 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT tangjiaojiao 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT fanzhecai 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT miaoyushan 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT dongyaping 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT taojunyan 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT mongasatdarshanps 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT wenwen 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara
AT wanghongyang 4phenylbutyricacidpromoteshepatocellularcarcinomaviainitiatingcancerstemcellsthroughactivationofppara